Novo Nordisk A/S
Outperforming asset supervisor picks the shares established to earn as margins get squeezed
Revenue margins are getting squeezed as inflation stays at elevated amounts, with a slew of firms — together with Walt Disney , PepsiCo and Spotify — all warning of margin pressures, casting a pall around earnings growth in the quarters forward. Patrick Armstrong, main financial investment officer at Plurimi Prosperity, thinks this is the “most […]
Read More
Market place veteran says a new bull marketplace is ‘not much away’ — and reveals how to participate in it
The stock sector has expert a sequence of bear marketplace rallies this year. And even though these small-lived bounces can be challenging to distinguish from a genuine current market bottom, one particular financial commitment professional believes a turnaround is on the horizon. “I believe buyers at this issue really should be on the lookout ahead […]
Read More
New obesity drugs win support of doctors and insurers, which could lift these pharma names even higher
Drugs that treat obesity and overweight are improving their efficacy. They are also increasingly being prescribed by doctors and covered by insurers – a win for patients and for investors. “While supply is still a top concern for Wegovy, we’ve been impressed with commercial formulary access for obesity,” Geoff Meacham, an analyst at Bank of […]
Read More
A recession seems to be progressively possible. But Goldman Sachs states these stocks could beat the gloom
Central banking institutions are relentlessly climbing interest premiums to rein in inflation — even at the expenditure of financial expansion — prompting fears of a recession. Goldman Sachs reported it believes the United States is established for a “soft landing. The bank’s main European economist Jari Stehn expects Europe to tip into a recession this […]
Read More
Eli Lilly’s 2022 gains grow to 20% as it lays out plan for possibly the most successful drug ever
Eli Lilly’s obesity treatment tirzepatide has been granted “fast track” status by the Food and Drug Administration, which means it could win approval as early as late 2023. The drug, which was already approved to treat type 2 diabetes under the name Mounjaro in May, has the potential to be a blockbuster, analysts have said. […]
Read More
Eli Lilly’s obesity medication looks poised to become a $100 billion a year drug
Bank of America expects Eli Lilly’s Mounjaro could generate as much as $100 billion in annual sales by 2035, if it’s approved to treat obesity and several other illnesses. The Food and Drug Administration granted approval in May to the once-weekly injection for the treatment of Type 2 diabetes. However, the company is actively looking […]
Read More
This fund manager is beating the market — and he has 4 tips for investors
It’s a tough year to be in the stock market, given the seemingly never-ending cycle of gyrations. Inflationary pressures remain elevated and with the Federal Reserve poised to pursue a more aggressive rate hike policy , a recession could be on cards. So how should investors trade this volatility? Fund manager Freddie Lait, a long-term […]
Read More
Investment banks say it’s time to get back into China, with Goldman naming 10 top stocks
China’s reopening after weeks of big-city lockdowns is “enticing” investors, according to HSBC , while Goldman Sachs has named a raft of stocks it says are at attractive valuations. Both Shanghai and Beijing have started to relax their Covid restrictions after weeks of strict lockdowns. This opening-up — combined with soaring government investment and plummeting […]
Read More
Goldman Sachs says a new investment cycle is coming — and names the stocks that could win
Goldman Sachs says we’re entering a new, “postmodern” investment cycle. Here’s what the bank thinks is in store — and the stocks investors should own to cash in. The emerging cycle — post the Covid pandemic — is likely to be driven by different economic conditions and priorities, leading to new investment opportunities, the bank […]
Read More
Eli Lilly obesity drug delivers 20% weight loss, bolstering investment case for new therapies
Tirzepatide is among a wave of new weight loss therapies poised to hit the market that are making greater amounts of weight loss possible. Source
Read More